Kineticos Disruptor Fund II, L.P.

Late investment period

Late investment period: first sale Dec 2021, per Form D (fund age approximates vintage)

Vintage: 2021
Fund size: $55.2M to $100M (Form D)
Stages: Not stated
Sectors: Biotech, Medical devices
Regions: Global

01 · Thesis

Kineticos Disruptor Fund II, L.P. invests in early-stage life science companies that are advancing breakthrough technologies to treat cancer, neurodegenerative diseases, and rare diseases.

02 · Initial check

$552K to $1.67M (estimated from fund size)

Estimated from Form D: $55.2M sold of a $100M target

03 · Who to approach

Named on this fund's Form D

Shailesh Maingi, Founder, Managing Partner
Frank Lis

04 · Deals

No deals attributed to this fund yet.

05 · Evidence

The Kineticos Disruptor Fund Series invests in early-stage life science companies advancing breakthrough technologies to treat cancer, neurodegenerative, and rare diseases.
We partner with companies advancing breakthrough technologies to tackle cancer, and neurodegenerative and rare diseases.
https://www.kineticos.com/kineticos-disruptor-fund-series/

06 · Sources

Last verified: Oct 25, 2026